Clinical trials: Asthma Patients
Asthma
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the…
- Trial name
- UNIK (NCT01167010)
- Testing
- Formoterol/Budesonide, Foraseq, Alenia
- Where
- 5 sites in Brazil
- Volunteers
- 552 people
- Sponsor
- Eurofarma Laboratorios S.A.
Bronchial Asthma
Fasenra Pediatric Japan Post-Marketing Study(PMS)
The purpose of the investigation is to confirm the followings under the post-marketing actual use of Fasenra® Subcutaneous Injection 30 mg / 10mg Syringe (hereinafter referred to as Fasenra). 1.
- Trial name
- NCT06427876
- Where
- 9 sites in Japan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Rhinitis, Conjunctivitis
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ
- Conditions
- Rhinitis, Conjunctivitis, Asthma
- Trial name
- NCT00857779
- Testing
- subcutaneous immunotherapy
- Where
- Germany
- Volunteers
- 473 people
- Sponsor
- ALK-Abelló A/S
Asthma
An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma
This is an observational, descriptive, open-label, prospective, 6-month study including a group of patients with a first prescription of IND/GLY/MF with sensor and a group with a first prescription of IND/GLY/MF without sensor.
- Trial name
- SENSE (NCT05120986)
- Testing
- IND/GLY/MF
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tests performed on one day
- Trial name
- NCT00272753
- Testing
- budesonide/formoterol Turbuhaler, formoterol Turbuhaler, salbutamol
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Allergic Asthma
Trial of JYB1904 in Patients With Allergic Asthma
This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.
- Trial name
- NCT06438757
- Testing
- JYB1904, Omalizumab
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Jemincare
Asthma
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks.
- Trial name
- NCT00442351
- Testing
- Asmanex twisthaler
- Volunteers
- 26 people
- Sponsor
- Organon and Co
Asthma
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
- Trial name
- NCT01103037
- Testing
- QAV680
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device
Phase IIa, single-centre, open-label, single-arm study, to evaluate the inspiration profile through the NEXThaler® device in adult asthmatic patients with varying degrees of disease control.
- Trial name
- NEXThalerPIF (NCT01651650)
- Testing
- Inhalation through Chiesi NEXThaler DPI
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Characteristics of Pts Initiating Spiriva Respimat in Asthma
This study is a cross-sectional, non-interventional study based on existing data (NISed).
- Trial name
- NCT03692676
- Testing
- Spiriva Respimat
- Where
- Germany
- Volunteers
- 116,133 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study in Mild Asthmatic Patients
The purpose of this study is to determine the safety and usefulness of GSK2190915 in asthmatic patients who develop asthma symptoms following being challenged.
- Trial name
- NCT00748306
- Testing
- GSK2190915 - 100mcg
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366
CHF6366 is a novel bifunctional compound displaying both muscarinic receptor antagonist and β2-adrenergic receptor agonist properties (MABA), with the potential to deliver optimal bronchodilation after inhalation dosing via two…
- Trial name
- NCT03378648
- Testing
- CHF6366, umeclidinium bromide and vilanterol trifenatate
- Where
- United Kingdom
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Mild Atopic Asthma
A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma
This randomized, observer-blinded, placebo-controlled, single and multiple ascending-dose study will be conducted in two parts to evaluate the safety, pharmacokinetics, and immunogenicity of BITS7201A.
- Trial name
- NCT02748642
- Testing
- BITS7201A
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Asthma
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants…
- Trial name
- NCT01312961
- Testing
- Dupilumab, Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy
- Where
- 50 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sanofi
Asthma
To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma
This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to…
- Trial name
- NCT01568762
- Testing
- VAK694, QAX576
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
The primary objective of this study is to compare the efficacy and safety of budesonide HFA MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler) 100 mcg 4 puffs BID in Chinese mild to moderate Asthma patients.
- Trial name
- NCT05152355
- Testing
- Budesonide 200 microgram/Puff, HFA MDI, Budesonide 100 microgram/Actuation Powder for Inhalation
- Where
- 13 sites in China
- Volunteers
- 270 people
- Sponsor
- Intech Biopharm Ltd.
Asthma, Compliance, Patient
COMPLliancE and qualiTy of lifE in Asthma
A multicenter, open, non-interventional, prospective, clinical observational study on Conformity to Therapy and Quality of Life in Asthma in patients living in Greece
- Conditions
- Asthma, Compliance, Patient, Quality of Life
- Trial name
- COMPLETE (NCT03300076)
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days.
- Trial name
- NCT00549744
- Testing
- GSK256066
- Where
- 3 sites in New Zealand, South Africa
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Asthma
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo.
- Trial name
- NCT01340209
- Testing
- Tiotropium Respimat
- Where
- 55 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Boehringer Ingelheim
Asthma
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
This study is designed to investigate the ability of patients with asthma to properly use a new multi-dose dry powder inhaler (MDDPI) device in a real-life situation.
- Trial name
- NCT00130351
- Testing
- formoterol
- Where
- 12 sites in United States
- Volunteers
- 155 people
- Sponsor
- Novartis